ACSL4 was also regarded as a biomarker for hormone resistance in human breast cancer 46, and as an mTOR and ERα regulator to restore tumour hormone dependence in tumours with poor prognosis, showing that inhibition of activity of ACSL4 produces a reduction in the expression of the mTOR signalling and restores the sensitivity to tamoxifen 44. This evidence concerns the gene MTOR and neoplasm.